CareDx, Inc. (NASDAQ:CDNA - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $11.81, but opened at $12.31. CareDx shares last traded at $12.11, with a volume of 1,062,812 shares.
Analyst Ratings Changes
CDNA has been the subject of a number of research analyst reports. Stephens reaffirmed an "overweight" rating and issued a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. Craig Hallum decreased their price target on CareDx from $40.00 to $26.00 and set a "buy" rating for the company in a research report on Friday. HC Wainwright reissued a "neutral" rating and set a $25.00 price objective on shares of CareDx in a report on Monday, May 5th. Wall Street Zen lowered CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, The Goldman Sachs Group reduced their price objective on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, CareDx presently has an average rating of "Moderate Buy" and an average price target of $29.33.
View Our Latest Analysis on CareDx
CareDx Stock Up 0.8%
The stock has a 50-day simple moving average of $18.23 and a two-hundred day simple moving average of $19.52. The firm has a market cap of $663.15 million, a PE ratio of 10.36 and a beta of 2.19.
CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a return on equity of 21.16% and a net margin of 19.79%. The company's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) earnings per share. Research analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current year.
Insiders Place Their Bets
In other CareDx news, Director Hannah Valantine sold 10,570 shares of CareDx stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $19.16, for a total transaction of $202,521.20. Following the sale, the director directly owned 38,994 shares of the company's stock, valued at approximately $747,125.04. The trade was a 21.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Peter Maag sold 10,000 shares of CareDx stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $18.58, for a total transaction of $185,800.00. Following the transaction, the director owned 308,846 shares of the company's stock, valued at $5,738,358.68. The trade was a 3.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 139,078 shares of company stock valued at $2,419,915 over the last three months. Company insiders own 4.40% of the company's stock.
Hedge Funds Weigh In On CareDx
A number of hedge funds have recently added to or reduced their stakes in CDNA. MCF Advisors LLC raised its holdings in CareDx by 292.9% in the 2nd quarter. MCF Advisors LLC now owns 1,336 shares of the company's stock worth $26,000 after purchasing an additional 996 shares during the period. Sterling Capital Management LLC raised its holdings in CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after purchasing an additional 1,126 shares during the period. PNC Financial Services Group Inc. raised its holdings in CareDx by 20,200.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock worth $79,000 after purchasing an additional 4,444 shares during the period. Tower Research Capital LLC TRC raised its holdings in CareDx by 553.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after purchasing an additional 3,322 shares during the period. Finally, State of Wyoming bought a new position in CareDx in the 4th quarter worth $91,000.
About CareDx
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
See Also
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
